169 related articles for article (PubMed ID: 17033446)
1. Anastrozole-induced hepatotoxicity.
Zapata E; Zubiaurre L; Bujanda L; Piérola A
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1233-4. PubMed ID: 17033446
[TBL] [Abstract][Full Text] [Related]
2. Anastrozole-related acute hepatitis with autoimmune features: a case report.
Inno A; Basso M; Vecchio FM; Marsico VA; Cerchiaro E; D'Argento E; Bagalà C; Barone C
BMC Gastroenterol; 2011 Mar; 11():32. PubMed ID: 21453541
[TBL] [Abstract][Full Text] [Related]
3. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
4. Extended adjuvant therapy for breast cancer--how much is enough?
Prowell TM; Stearns V
J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
[No Abstract] [Full Text] [Related]
5. Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Bremec T; Demsar J; Luzar B; Pavlović MD
Dermatol Online J; 2009 Jul; 15(7):14. PubMed ID: 19903442
[TBL] [Abstract][Full Text] [Related]
6. ATAC trial update.
de Castro G
Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811448
[No Abstract] [Full Text] [Related]
7. Severe acute hepatitis in a patient treated with anastrozole.
de la Cruz L; Romero-Vazquez J; Jiménez-Sáenz M; Padron JR; Herrerias-Gutierrez JM
Lancet; 2007 Jan; 369(9555):23-4. PubMed ID: 17208628
[No Abstract] [Full Text] [Related]
8. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Bock VL; Friedlander M; Waring D; Kossard S; Wood GK
Australas J Dermatol; 2014 Nov; 55(4):282-5. PubMed ID: 24575835
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of aromatase inhibition for breast cancer.
Toi M
Lancet Oncol; 2008 Jan; 9(1):8-10. PubMed ID: 18177815
[No Abstract] [Full Text] [Related]
10. Grover disease (transient acantholytic dermatosis) induced by anastrozole.
Crockett JS; Burkemper NM
Cutis; 2011 Oct; 88(4):175-7. PubMed ID: 22106724
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid prevents cancer treatment-induced bone loss.
Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
[No Abstract] [Full Text] [Related]
12. [Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
Nemitz N; Kurmann PT; Van Linthoudt D
Praxis (Bern 1994); 2008 Feb; 97(3):137-41. PubMed ID: 18549014
[TBL] [Abstract][Full Text] [Related]
13. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
14. Lichen sclerosus in a breast cancer survivor on an aromatase inhibitor: a case report.
Potter JE; Moore KA
J Gen Intern Med; 2013 Apr; 28(4):592-5. PubMed ID: 22956445
[TBL] [Abstract][Full Text] [Related]
15. A woman with breast cancer and severe impaired lactose tolerance: an intriguing therapeutic dilemma.
Zagouri F; Dimitrakakis C; Dimopoulos MA; Tsigginou A; Antsaklis A; Papadimitriou CA
Breast J; 2012; 18(6):628-9. PubMed ID: 23009609
[No Abstract] [Full Text] [Related]
16. Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Altundag K; Dede D; Harputluoglu H; Gullu I
Joint Bone Spine; 2007 Dec; 74(6):662-3. PubMed ID: 17913550
[No Abstract] [Full Text] [Related]
17. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
18. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Nabholtz JM
Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
[TBL] [Abstract][Full Text] [Related]
19. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
[TBL] [Abstract][Full Text] [Related]
20. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
